Compare · ELV vs SERA
ELV vs SERA
Side-by-side comparison of Elevance Health Inc. (ELV) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.24B, about 1006.3x SERA ($89.7M).
- Over the past year, ELV is up 7.4% and SERA is up 43.9% - SERA leads by 36.6 points.
- SERA has been more active in the news (9 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 8 for SERA).
- Company
- Elevance Health Inc.
- Sera Prognostics Inc.
- Price
- $418.31+0.63%
- $2.13-6.99%
- Market cap
- $90.24B
- $89.7M
- 1M return
- +12.19%
- +16.39%
- 1Y return
- +7.35%
- +43.92%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 9
- Recent ratings
- 23
- 8
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest SERA
- SEC Form 144 filed by Sera Prognostics Inc.
- Sera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Elliott Jeffrey Thomas
- Craig Hallum initiated coverage on Sera Prognostics with a new price target
- General Counsel Jackson Benjamin was granted 5,000 shares, increasing direct ownership by 3% to 163,935 units (SEC Form 4)
- Chief Commercial Officer Anderson Dyaarl Lee Jr. was granted 3,168 shares, increasing direct ownership by 4% to 82,737 units (SEC Form 4)
- SEC Form DEFA14A filed by Sera Prognostics Inc.
- Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
- SEC Form 4 filed by Chief Data Officer Kearney Paul